Transcripts - Participants Matt Kapusta, Chief Executive Officer Ricardo Dolmetsch, President of R&D Sara Tabrizi, KOL Maria Cantor, Chief Corporate Affairs Officer Maria Cantor, Chief Corporate Affairs Officer Good morning, … Continue Reading
Read nowInsights - Gene therapy companies were down big yesterday after bluebird bio (BLUE) announced that they will temporarily suspend their sickle cell disease programs. bluebird bio was down 37% … Continue Reading
PremiumInsights - Magenta (MGTA) is pursuing two of the largest challenges in stem cell transplants; mobilizing stem cells and conditioning patients for transplants. Overcoming these challenges will … Continue Reading
PremiumInsights - Adverum (ADVM) has rallied year to date from $3.50 to $10/share as the market is picking up on the gene therapy story. With data in … Continue Reading
PremiumResearch - Over the weekend, the scientific and investing communities had a first look at 1-year follow-up results for AMT-110, uniQure’s (QURE) gene therapy candidate for the treatment of Sanfilippo B.
Read nowResearch - UniQure’s (QURE) presentation of 1-year follow-up data from patients with Sanfilippo B (MPS IIIB) and treated with the gene therapy AMT-110 is only a week … Continue Reading
Read nowInsights - Bluebird bio (BLUE) keeps hitting its marks. The first Sickle Cell patient treated with LengiGlobin, bluebird’s one-time gene therapy product, is producing healthy red blood cells, … Continue Reading
Read now
